Skip to main content

Research Repository

Advanced Search

Cost-effectiveness of HCC Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom

Garay, Osvaldo Ulises; Ambühl, Louisa Elena; Bird, Thomas G; Barnes, Eleanor; Irving, William L; Walkley, Ryan; Rowe, Ian A

Cost-effectiveness of HCC Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom Thumbnail


Authors

Osvaldo Ulises Garay

Louisa Elena Ambühl

Thomas G Bird

Eleanor Barnes

William L Irving

Ryan Walkley

Ian A Rowe



Abstract

This study aimed to evaluate the cost-effectiveness (CE) of four hepatocellular carcinoma (HCC) surveillance strategies in the UK, the GAAD algorithm, which combines gender (biological sex) and age with Elecsys® biomarker assays, alpha-fetoprotein (AFP) and protein induced by vitamin K absence-II (PIVKA-II), ultrasound (US), US+AFP and GAAD+US. A de novo micro-simulation state-transition Markov model was developed in Microsoft Excel® from the perspective of the UK National Health Service to calculate life years, quality-adjusted life-years (QALYs), costs, incremental CE ratios, and net monetary benefits. Parameters were sourced from peer-reviewed published literature, national guidelines, and public cost databases. Sensitivity and scenario analyses were performed to evaluate the impact of parameter and structural uncertainty on the results. In a simulated cohort of 100,000 patients, discounted costs and QALYs per patient were £8,663 and 6·066 for US, £9,095 and 6·076 for US+AFP, £8,719 and 6·078 for GAAD alone, and £9,114 and 6·086 for GAAD+US. At a CE threshold of £20,000/QALY, GAAD was the most cost-effective strategy; however, although most costly, GAAD+US was the most clinically effective. Sensitivity and scenario analyses indicated that HCC incidence along with costs associated with diagnostic performance influence CE. Considering the cost of US and low incidence of HCC in the UK, this study suggests that GAAD alone or in combination with US are cost-effective surveillance strategies compared with US and US+AFP. Whilst GAAD+US showed the highest QALY increase, GAAD alone is considered preferable regarding CE; however, better performance estimates for GAAD+US are needed to confirm. [Abstract copyright: Copyright © 2024. Published by Elsevier Inc.]

Citation

Garay, O. U., Ambühl, L. E., Bird, T. G., Barnes, E., Irving, W. L., Walkley, R., & Rowe, I. A. (2024). Cost-effectiveness of HCC Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom. Value in Health, https://doi.org/10.1016/j.jval.2024.07.015

Journal Article Type Article
Acceptance Date Jul 27, 2024
Online Publication Date Aug 8, 2024
Publication Date Aug 8, 2024
Deposit Date Sep 12, 2024
Publicly Available Date Sep 12, 2024
Journal Value in Health
Print ISSN 1098-3015
Electronic ISSN 1524-4733
Publisher Elsevier
Peer Reviewed Peer Reviewed
DOI https://doi.org/10.1016/j.jval.2024.07.015
Keywords GAAD, biomarker algorithm, surveillance, cost-effectiveness, HCC
Public URL https://nottingham-repository.worktribe.com/output/38897748
Publisher URL https://www.sciencedirect.com/science/article/pii/S1098301524027980

Files





Downloadable Citations